How to Choose an Oxygen Concentrator

What DME suppliers, home health agencies, and discharge planners need to know before specifying stationary or portable units for long-term oxygen therapy programs.

---

What this is and who buys it

An oxygen concentrator is a mains- or battery-powered device that separates oxygen from ambient room air using a process called pressure swing adsorption (PSA), delivering a concentrated oxygen stream — typically 87–96% purity — directly to the patient through a nasal cannula or mask. Unlike compressed gas cylinders, concentrators generate oxygen continuously on-site, eliminating the logistics of cylinder refills and the associated hazard management. That convenience is why they have become the default technology for long-term oxygen therapy (LTOT) in both home and ambulatory settings.

The primary buyers are durable medical equipment (DME) suppliers, home health agencies managing patient populations with COPD, hypoxemia, or pulmonary fibrosis, and hospital discharge planning departments standing up outpatient respiratory programs. In each of those settings, the device isn't purchased once — it's procured as a fleet, often numbered in the dozens or hundreds, which means small differences in power draw, failure rates, and service costs compound significantly over time. A procurement decision that looks straightforward at the unit level can carry material financial and clinical consequences at scale.

Two distinct form factors serve different clinical needs. Stationary continuous-flow concentrators are AC-powered bedside units rated at 1–10 LPM; they are the workhorse of home LTOT programs. Portable oxygen concentrators (POCs) are battery-powered and compact, designed for ambulatory patients who need oxygen outside the home. Most POCs use pulse-dose (breath-triggered) delivery, which conserves battery life but requires physician confirmation that the patient's breathing pattern is adequate to trigger reliable dose delivery — a clinical nuance that has direct implications for which product you should be specifying.

---

Key decision factors

Delivery mode — continuous flow versus pulse dose is arguably the single most consequential specification decision. Stationary units produce continuous flow in the 1–5 LPM range for standard home models, up to 10 LPM for high-output units capable of serving higher-acuity patients. Continuous flow is non-negotiable for patients on nocturnal oxygen therapy, those with shallow or irregular breathing, and pediatric patients — none of whom can reliably trigger a pulse-dose sensor. Before specifying a POC for any individual patient, the prescribing physician must document that pulse-dose delivery is clinically sufficient; this is a regulatory and liability issue, not just a product preference.

Oxygen purity output is defined by ISO 80601-2-69:2014, which sets the minimum acceptable concentration at 82% O₂ at rated flow. In practice, clinical-grade units are rated at 93% ± 3%. When evaluating competing models, request a third-party purity test report rather than relying on the manufacturer's specification sheet alone — rated purity at low flow does not always predict performance at maximum LPM output, particularly as sieve beds age.

Flow rate accuracy at rated load matters more than it might appear in catalogue descriptions. Rated LPM figures are typically measured under ideal bench conditions; real-world performance can degrade under back-pressure from long cannula tubing or in high-altitude deployments. Facilities in locations above 9,000 feet above sea level should specify units that have been validated for high-altitude operation, since atmospheric oxygen partial pressure at elevation reduces concentrator output measurably.

Power consumption and total operating cost is one of the most under-evaluated variables in fleet procurement. Stationary 5 LPM concentrators draw roughly 150–600W depending on model and age of design. For a DME supplier running a fleet of 200 units averaging 18 hours of daily use, even a 100W difference per unit translates to a meaningful annual electricity cost — often exceeding the capital cost of the units themselves over a five-year horizon. Build energy TCO into every fleet evaluation using local kWh rates and realistic daily run-hours rather than simply comparing purchase price.

Acoustic output is regulated under ISO 80601-2-69:2014, which requires sound level testing per ISO 3744. Stationary units typically range from 40–55 dB(A) measured at one metre. For bedroom-deployed units, 45 dB(A) or below is the practical ceiling for sleep-compatible operation. Request the manufacturer's measured test documentation, not an estimated figure from a brochure, since acoustics vary meaningfully across flow settings.

Alarm completeness is a patient safety specification. ISO 80601-2-69:2014 mandates an audible alarm for low oxygen purity, but a minimum-compliant device may not alarm on power interruption or cannula disconnection. For unattended home use — which is essentially all home LTOT — confirm the unit also carries power-failure and no-flow alarms. These are not optional enhancements; they are clinical requirements for safe deployment.

Connectivity and remote monitoring is increasingly relevant to DME billing and payer compliance. Several current-generation POCs offer Bluetooth telemetry that documents patient usage and compliance data, which some payers require to authorise continued long-term oxygen therapy reimbursement. When evaluating connectivity-enabled units, assess whether the manufacturer's telemetry platform integrates with your billing software or EHR — a proprietary data silo that doesn't connect to your workflows adds administrative burden rather than reducing it.

FAA acceptance is mandatory for any POC specified for ambulatory patients who may travel by air. Under 14 CFR Part 382, carriers are required to permit FAA-accepted POCs on commercial flights, but acceptance is model-specific and documented via a manufacturer Letter of Authorization (LOA). Do not rely on general "airline-approved" marketing language; request the actual LOA for each specific model number being evaluated.

---

What it costs

Oxygen concentrator pricing spans a wide range depending on form factor, output capacity, and connectivity features. Retail pricing is not consistently published by all distributors, and MAP (minimum advertised price) policies mean that formal quotes from channel partners are often required for accurate current pricing. The figures below reflect approximate market positioning as of recent procurement cycles; treat them as orientation rather than binding reference.

• Entry tier — $595–$900: Stationary 5 LPM continuous-flow units with no connectivity features. Units in this range (such as the CAIRE Companion 5 at approximately $800, or the Philips Respironics EverFlo in the $595–$750 range) are workhorses for basic home LTOT programs where simplicity and low operating cost matter more than telemetry.
• Mid tier — $900–$2,500: Stationary high-output (10 LPM) units, mid-range POCs with pulse-dose delivery, and refurbished continuous-flow portables from authorized remarketers. This band covers most clinical expansion scenarios.
• Premium tier — $2,500–$4,000+: Continuous-flow POCs with Bluetooth telemetry. Examples include Inogen POC models in the $2,295–$3,465 range, Philips Respironics SimplyGo variants at $2,495–$3,295, and comparable platforms from other manufacturers — all subject to MAP policies and channel. Request formal quotes; published prices are not always final prices.

---

Common use cases

Oxygen concentrators are appropriate wherever a reliable, on-site oxygen source is preferable to cylinder logistics, but the clinical and operational context shapes which configuration is correct.

• Home LTOT for COPD and pulmonary fibrosis patients: Stationary 5 LPM continuous-flow units remain the standard of care, typically deployed at bedside with supplemental cylinder backup for power outages.
• Ambulatory and travel-capable therapy: Battery-powered POCs with FAA LOA for patients who remain active, travel frequently, or require oxygen outside the home for extended periods.
• High-acuity home patients: 10 LPM high-output stationary units for patients whose prescription exceeds standard 5 LPM capacity, including some post-acute discharge cases.
• DME fleet deployment: Multi-unit procurement by DME suppliers or home health agencies managing geographically distributed patient populations, where energy efficiency, durability, and serviceability weigh as heavily as unit cost.

---

Regulatory and compliance

Oxygen concentrators are classified as FDA Class II medical devices, subject to 510(k) premarket notification. This means any unit sold in the United States must have a cleared 510(k) — verify the specific model's 510(k) number in the FDA's public device database before purchasing, particularly for unfamiliar brands or grey-market imports. The predicate device pathway does not eliminate performance variability between cleared products; clearance confirms regulatory status, not clinical equivalence.

The primary performance standard is ISO 80601-2-69:2014 (Medical electrical equipment — Particular requirements for basic safety and essential performance of oxygen concentrator equipment), which governs purity thresholds, alarm requirements, and acoustic testing methodology. In the United States, AAMI has adopted this standard, and conformance is expected by accreditation bodies. For home use specifically, CMS reimbursement policies under HCPCS code E1390 (and related codes for portable units) impose additional documentation requirements, including Certificate of Medical Necessity and, in some jurisdictions, compliance monitoring data — a requirement that is reshaping interest in telemetry-enabled devices. HIPAA implications arise when telemetry data is transmitted and stored; confirm the manufacturer's data handling practices if patient identifiable usage data flows through their platform.

---

Service, training, and total cost of ownership

Sieve beds — the zeolite molecular sieve material that performs the PSA separation — are the primary wear component in any oxygen concentrator and the main driver of long-term service cost. Most manufacturers rate their sieve beds for 20,000 hours or more of operation under normal conditions, which corresponds to roughly five to seven years at typical home use rates. Actual longevity depends heavily on operating environment: units deployed in humid climates or dusty settings will experience accelerated sieve bed degradation, and inlet filter maintenance — typically a monthly user cleaning task — is the single most effective preventive measure available to patients and caregivers.

Preventive maintenance protocols should include periodic purity verification using an inline oxygen analyser, because sieve bed degradation is gradual and may not trigger the low-purity alarm until the unit is meaningfully below rated output. For DME fleets, a structured PM schedule with documented purity checks on a defined cycle (often every 12 months per manufacturer guidance) is both a patient safety practice and a documentation requirement under some accreditation frameworks such as ACHC and The Joint Commission. Service contracts vary considerably: some manufacturers offer per-unit annual contracts covering parts and labour; others offer flat-rate depot repair. For large fleets, negotiate a blended contract that covers PM visits and purity verification, not just reactive repair. Training requirements are modest for stationary units — most DME technicians can set up and verify a stationary concentrator in under an hour — but POC training should include patient instruction on pulse-dose adequacy monitoring and battery management, both of which are common sources of therapy failure in the field.

---

Red flags to watch for

A manufacturer that cannot produce an ISO 80601-2-69:2014 conformance certificate or a completed purity test report on request — rather than just a spec sheet — is a signal that independent performance validation may not have been performed. This matters most for lower-cost imports where the 510(k) number alone does not guarantee consistent production quality.

"Airline-approved" language in marketing materials, without a model-specific FAA Letter of Authorization, is a compliance risk. Airlines are required only to accept devices that appear on the FAA's accepted POC list, and acceptance is tied to specific model numbers — a version change or rebrand can invalidate a prior LOA.

An unusually low wattage claim for a 5 LPM stationary unit warrants verification: PSA physics impose a practical lower bound on energy consumption, and figures that fall well below established comparable models may reflect testing at low flow rates, not at rated maximum output.

For connectivity-enabled units, the absence of any information about data security practices, HIPAA business associate agreement availability, or data ownership terms should be treated as a procurement risk, not just an IT footnote.

---

Questions to ask vendors

1. What is the 510(k) clearance number for this specific model, and can you provide the FDA submission summary?
2. Can you supply a third-party oxygen purity test report at maximum rated LPM, not just the manufacturer specification sheet?
3. What is the rated sound level in dB(A) at 1 metre as measured per ISO 3744, and at which flow setting was that measurement taken?
4. What is the published sieve bed service life in hours, and what are the manufacturer's recommended PM intervals and associated costs?
5. For POCs: what is the model-specific FAA Letter of Authorization number, and is this unit currently on the FAA accepted POC list?
6. If the unit has telemetry capability, who owns the usage data, where is it stored, and is a HIPAA Business Associate Agreement available?

---

Alternatives

The refurbished market for stationary concentrators is established and legitimate, provided units are sourced from authorized remarketers who document sieve bed hours, provide purity verification testing, and carry their own limited warranty. A refurbished 5 LPM unit with documented low hours and a purity test can be a sound fleet expansion strategy; a unit with unknown provenance and no purity documentation is a clinical liability regardless of price. For POCs, refurbishment is less common and the risk-benefit calculation is less favourable given the battery replacement cost and the importance of current FAA LOA status.

• Refurbished stationary units from authorized remarketers: viable for fleet expansion if sieve bed hours and purity documentation are provided.
• Leasing vs. buying for DME suppliers: Some manufacturers and distributors offer operating leases on concentrator fleets, which can preserve capital and shift maintenance responsibility; evaluate whether the lease structure includes PM and repair or simply defers capital expenditure.
• Cylinder backup: Not an alternative to concentrators for long-term home therapy, but a necessary complement — every home LTOT patient should have cylinder backup for power outages, and procurement plans should account for this.
• Liquid oxygen systems: Relevant for very high-flow patients (above 10 LPM) or specific clinical scenarios, but the logistics, fill infrastructure, and regulatory requirements make them a distinct procurement category, not a drop-in alternative to concentrators for most home programs.

---

Sources

No external source articles were available for this guide. The following primary references are directly relevant to claims made above and should be consulted for independent verification:

• ISO 80601-2-69:2014 — Medical electrical equipment: Particular requirements for oxygen concentrator equipment
• FDA 510(k) Premarket Notification Database — Search "oxygen concentrator"
• FAA Approved Portable Oxygen Concentrator List (14 CFR Part 382)
• CMS HCPCS Code E1390 — Home Oxygen Concentrator Coverage Criteria